Transformational Research & Rapid Response (Alzheimer’s & Related Diseases) – Letter of Intent
External Deadline: Monday 1st, April 2019
The Transformational Research: Canada program will now run concurrent with the Rapid Response: Canada Program and both programs will run continuously and more frequently throughout the year.
Applicants will be able to apply to the Rapid Response or the Transformational Research program depending on the specifics of the project (e.g., length, budget and preliminary data) and choose the disease stream that best suits their project (i.e. Parkinson’s and related diseases or Alzheimer’s and related diseases). Projects that span across both disease streams are still encouraged, we just ask the applicant to choose the stream that best fits their project. Please note, as the Canadian programs will now be running more frequently, submission deadlines are unlikely to be extended once announced.
New Program Updates – 2019
- 1. Rapid Response: Canada 2019 budget increased to $300k/project.
- 2. Transformational Research: Canada 2019 – No preliminary data is required and instead can be collected as initial steps in the grant.
- 3. Complementary approaches such as diet, physical activity, sleep, nutritional supplements, speech therapy, and cognitive therapy, are now eligible for funding through most of the funding programs.
- 4. Encouraging applications that bring in other fields such as: AI, big data, machine learning, data science, and computer science.
Rapid Response: Canada
Seed funding (up to $300,000 over up to 18 months) for novel, high-risk, high-reward translational research projects on neurodegenerative diseases of aging. Preliminary data is not required. Cycles of this program will run back-to-back going forward.
Project Eligibility: Project must involve the development of either a therapeutic, a tool, select complementary approaches, or a combination of above to help accelerate the development of therapeutics for neurodegenerative diseases of aging.
Transformational Research: Canada
Funding ($200,000 to $1,500,000 over up to 3 years) to fund transformative, novel, high-risk, high-reward translational research projects on neurodegenerative diseases of aging. Cycles of this program will run back-to-back going forward.
No preliminary data is required; instead it can be collected as an initial milestone with well defined, quantifiable go/no-go criteria. The structure of the project and budget should match the quality of the preliminary data.
Project Eligibility: Project must involve the development of either a therapeutic, a tool, select complementary approaches, or a combination of the above to help accelerate the development of therapeutics for neurodegenerative diseases of aging.
Alzheimer’s & Related Diseases (AD, FTD, MCI, prodromes, and vascular contributions to the listed diseases)
Program Information Webinar: February 27, 2019 at 1 pm EST (Register here)
LOI deadline: April 1, 2019 at 2 pm EDT
Proposal Deadline: July 30, 2019 at 2 pm EDT
Award announcement: October 2019
For more program information, please visit Weston’s website.